Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Perspective Therapeutics (NYSE American: CATX) announced that CEO Thijs Spoor will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026.
The company presentation is scheduled for 2:15–2:55 p.m. PT at The Westin St. Francis Hotel and will cover Perspective's radiopharmaceutical development programs targeting cancers throughout the body.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CATX gained 3.09%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While CATX was down 8.8%, peers showed mixed moves: TLSI -1.22%, OM -4.07%, QSI -3.23%, NNOX -6.23%, and CERS +0.23%, suggesting stock-specific factors rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 04 | Clinical data update | Positive | +8.1% | Acceptance of [212Pb]VMT-α-NET data for ASCO-GI 2026 presentation. |
| Nov 20 | Conference participation | Neutral | -7.8% | Announcement of participation in two December healthcare investor conferences. |
| Nov 10 | Earnings and update | Neutral | +1.4% | Q3 2025 results with clinical progress and funding into late 2026. |
| Oct 31 | Conference meetings | Neutral | +3.4% | Planned investor meetings and fireside chat at November conferences. |
| Oct 24 | Earnings pre-announcement | Neutral | +3.8% | Notice of upcoming Q3 2025 earnings release and business update. |
Recent news responses skew modestly positive, especially around clinical data and earnings updates, while some conference participation headlines have coincided with negative moves.
Over the last few months, CATX has reported Q3 2025 results with a net loss of $25.969M but liquidity of $174.1M as of Sep 30, 2025, and continued progress in its radiopharmaceutical pipeline. Clinical data updates for [212Pb]VMT-α-NET accepted for ASCO-GI 2026 coincided with a +8.14% move, while multiple conference participation announcements in October–November saw mixed reactions between about -7.83% and +3.82%. Today’s J.P. Morgan conference presentation fits this pattern of ongoing investor outreach and visibility efforts.
Market Pulse Summary
This announcement centers on CATX presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, a key venue for engaging institutional investors. It follows recent clinical data acceptances and Q3 2025 results that highlighted a $25.969M net loss but $174.1M in liquidity as of September 30, 2025. Investors may watch for any updated clinical details, partnership commentary, or refinement of strategic priorities shared during the 2:15–2:55 p.m. PT session.
Key Terms
radiopharmaceutical medical
AI-generated analysis. Not financial advice.
SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14, 2026, at 2:15 p.m. PT.
44th Annual J.P. Morgan Healthcare Conference – Company Presentation
Date: Wednesday, January 14, 2026
Time: 2:15 - 2:55 p.m. PT
Location: The Westin St. Francis Hotel, San Francisco, CA
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the ability of the Company's proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company’s prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
FAQ
When will Perspective Therapeutics (CATX) present at the J.P. Morgan Healthcare Conference?
Who is presenting for Perspective Therapeutics (CATX) at the January 14, 2026 conference?
Where is the Perspective Therapeutics (CATX) presentation at the J.P. Morgan Healthcare Conference being held?
How long is the Perspective Therapeutics (CATX) presentation scheduled to last on January 14, 2026?
What topics will Perspective Therapeutics (CATX) likely cover at the J.P. Morgan Healthcare Conference?
